Company

Product

Description

Indication

Status

Date

Phase II

Actinogen Medical Ltd., of Sydney

Xanamem

Blocks activity of 11beta-HSD1

Mild Alzheimer's disease

Enrolled the final patient in the XanADu trial; 186-patient trial is comparing Xanamem to placebo in patients with mild dementia due to AD; results expected in the second quarter of 2019

11/26/18

Opthea Ltd., of Melbourne, Australia

OPT-302

Soluble form of VEGFR-3

Wet age-related macular degeneration

Last patient enrolled in the phase IIb trial, with total of 366; top-line data expected in the fourth quarter of 2019

11/26/18

Phase III

Foresee Pharmaceuticals Co. Ltd., of Taipei, Taiwan

FP-001 (LMIS 25 mg)

Leuprolide mesylate injectable suspension

Advanced prostate cancer

All patients completed participation in the single-arm study; 144 patients enrolled to receive 2 consecutive injections for aggregated treatment duration of 6 months; top-line data expected in the first quarter of 2019

11/26/18


Notes

The date indicated refers to the BioWorld Clinical data table in which the news item can be found.

For more information about individual companies and/or products, see Cortellis.

 

No Comments